Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Faron Pharmaceuticals Ltd | Silence Therapeutics plc | Scancell Holdings Plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.

Faron Pharmaceuticals Ltd

RSS Portfolio


Faron Pharmaceuticals is a clinical stage drug discovery and development company based in Turku, Finland. Faron has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. Implementing the strategy of creating a novel treatment for significant unmet medical needs, Faron has now entered into a pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). Currently there is no available drug treatment for ARDS, an orphan lung disease coupled with a reported mortality rate of approximately 30 to 45%. Although ARDS is not common, there are about 170 000 patients annually in Europe and nearly 200 000 in the US.

Market: AIM
52-week High/Low: 890.00p / 54.00p
Market Cap: 36.15M

View full company profile

Scancell Holdings Plc

RSS Portfolio


Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

Market: ISE
52-week High/Low: 18.51p / 9.22p
Market Cap: 39.75M

View full company profile

Silence Therapeutics plc

RSS Portfolio


Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

Market: AIM
52-week High/Low: 254.75p / 110.00p
Market Cap: 82.80M

View full company profile

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use